Did you know this version of Internet Explorer is out of date?

To get the latest experience from our website, please upgrade your browser.

Have a drug or medical device concern?

call

Invokana

Invokana belongs to a newer class of Type 2 diabetes treatments called sodium-glucose co-transporter 2 (SGLT2) inhibitors, a class of medication that works by stopping glucose from being reabsorbed into the blood. The FDA warned Invokana can also cause ketoacidosis, a condition that requires hospitalization and can cause fatal swelling of the brain, severe dehydration and coma.

How Invokana Works

While many drugs work to increase insulin, Invokana works by stopping glucose from being reabsorbed into the blood in the kidneys. It acts by inhibiting a special protein in the kidney called SGLT2 that is responsible for reabsorbing 90 percent of the glucose in the kidneys. Instead of reabsorbing the sugar, the kidneys secrete it, and it leaves the body during urination. This results in lowered levels of glucose in the blood.

What Are the Side Effects of Invokana?

The most common Invokana side effects include:

  • Diabetic Ketoacidosis
  • Kidney Injury
  • Urinary Tract Infections
  • Cardiovascular Problems

Recent studies and FDA warnings link Invokana to a number of serious side effects that may be fatal. Many of these side effects also require hospitalization and intensive care or emergency treatment.

Diabetic Ketoacidosis

In May 2015, the FDA warned that Invokana may lead to a serious condition called diabetic ketoacidosis (DKA). DKA occurs when the body cannot use sugar (glucose) as a fuel source because there is either too little or no insulin. Instead, the body breaks down fat for energy. The breakdown of fat produces ketones which can build up in the body. When these waste products build up in the blood, they become toxic.

According to the FDA warning, the agency received about 20 reports of ketoacidosis in patients treated with SGLT2 inhibitors from March 2013 to June 6, 2014. All of these patients needed to go to the hospital for treatment. Since then, the FDA said they are still receiving reports of ketoacidosis in relation to these drugs. The agency ordered manufacturers to add warnings to the drugs' labels in December 2015.

DKA is a serious condition and patients who notice any of these symptoms should contact a doctor or emergency room immediately.

Symptoms of DKA include:

  • Confusion
  • Difficulty breathing
  • Unusual fatigue or sleepiness
  • Stomach pain
  • Flushed face
  • Fruity-smelling breath
  • Aching muscles or muscle stiffness
  • Vomiting and nausea
  • Frequent urination or thirst that lasts for a day or more

Kidney Injury

In June 2016, the FDA strengthened the acute kidney injury (AKI) warning for Invokana. Kidney injury is a serious condition where the kidneys suddenly stop working and allow waste to build up in the body. According to the FDA, more than 100 people reported suffering kidney injury after taking Invokana or another SGLT2 drug, Farxiga, between March 2013 and October 2015. The agency says there may be more unreported cases. About half of reported cases occurred within one month of starting the drug.

In some cases, AKI may not have symptoms, and healthcare providers may have to run some tests to diagnose it. The FDA recommends patient who have signs of kidney injury stop taking Invokana immediately.

Symptoms of AKI include:

  • Chest pain or pressure
  • Confusion
  • Fatigue or tiredness
  • Nausea
  • Seizures or coma in severe cases
  • Shortness of breath
  • Too little urine leaving the body
  • Swelling in legs, ankles, and around the eyes

Blood Infection and Urinary Tract Infections (UTIs)

In December 2015, the FDA warned that Invokana can increase the risk of serious or life-threatening blood infections (urosepsis) that started as UTIs. The agency identified 19 cases of blood infections and kidney infections (pyelonephritis) from March 2013 to October 2014.

The FDA recommends that patients contact a healthcare provider immediately if they suffer these symptoms.

Symptoms of UTIs include:

  • A burning feeling when urinating
  • A need to urinate often
  • The need to urinate right away
  • Blood in the urine
  • Pain in the lower part of your stomach area (pelvis)

Symptoms of blood infection include:

  • Fever
  • Chills
  • Rapid breathing
  • Paleness
  • Heart palpitations or increased heart rate

Cardiovascular Problems

The FDA also required Johnson & Johnson to conduct post marketing studies and a clinical trial after initial study data showed a troubling increase in the risk of cardiovascular problems such as stroke, blood clots (thromboembolic events) and heart attacks. The CANVAS trial showed a 46 percent elevated risk for stroke in the first 30 days of treatment.

Invokana and Acute Pancreatitis

In 2016, the FDA said it received reports of acute pancreatitis in patients taking Invokana and other SGLT2 inhibitors. Acute pancreatitis occurs when the pancreas, the organ responsible for making insulin, becomes inflamed and swollen. It can lead to serious health problems and death if untreated. Treatment for mild cases typically involves antibiotics. For more serious cases, doctors may hospitalize patients for emergency treatment.

In its Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) list from April to June 2016, the agency said it was "evaluating the need for regulatory action" for acute pancreatitis for all drugs in the class.

A handful of the studies on acute pancreatitis and SGLT2s primarily focus on case reports related to Invokana.

One case study from 2015 published in Therapeutics and Case Management by Dr. Mudit Chowdhary and colleagues treated a patient who reported to the ER after experiencing vomiting, pain and nausea for two days. They concluded it was acute pancreatitis caused by Invokana.

In a second 2015 case study written by Dr. Narat Srivali and colleagues in the Journal of Basic Clinical Pharmacy, a patient developed diabetic ketoacidosis caused by acute pancreatitis after taking Invokana for four days. Doctors determined Invokana caused the problems.

Both patients recovered after they stopped taking Invokana.

The most common side effects were:
Dehydration and thirst Discomfort during urination
Increased urination Increased Cholesterol
Kidney problems Low blood sugar
Urinary tract infections Yeast infections in men and women
Fatigue Vaginal itching
Constipation Nausea

Contraindications

SGLT2 inhibitors may work in each person differently, namely in pregnant women, nursing mothers, children and older people. These drugs are not FDA-approved for use in patients with Type 1 diabetes or people with diabetic ketoacidosis (DKA) or a history of DKA. Patients with kidney problems also should not use these drugs.

Who Should Not Use Invokana?

Pregnant Women

This drug has a pregnancy risk category of C. This means there are no tests or data from pregnant women and risk cannot be ruled out. But in rats, Invokana affected kidney development. These medications should only be used if the risk outweighs the benefit.

Nursing Mothers

There are no tests to determine if these drugs are excreted in human breast milk, but levels of the drug were found in the milk of rats. There may be risk to the developing human kidney if babies ingest milk with traces of these drugs. Before breastfeeding, mothers should talk to their doctors.

Use in Children

The safety or effectiveness of these drugs has not been tested in children under 18.

Seniors

Clinical studies show that patients 65 and older typically suffer more side effects from these medications. With Invokana, patients suffered from low blood pressure, dizziness and dehydration. The drugs were less effective in older people with poor kidney function. These drugs also caused more kidney failure in older patients. These side effects worsened for patients 75 or older.

Clinical Studies

Placebo-controlled clinical trials for Invokana involved 584 participants who had Type 2 diabetes that was not controlled with diet and exercise. The trial lasted 26 weeks. The average age was 55 years old. At the end of the trial people who took Invokana achieved an HbA1C less than 7 percent.

In four studies for the safety of the drug, 1,667 patients took Invokana for about 24 weeks. Most people in the study had Type 2 diabetes for about 7 years. In the study, the most common side effects participants suffered were yeast infections and urinary tract infections. About 10 percent of women and 4 percent of men suffered from yeast infections because of the large amount of sugar in urine.

Invokamet (canagliflozin and metformin) takes the active ingredient in Invokana and adds metformin. Because of this, the drug has a black box warning for lactic acidosis. If patient suspects this condition, they should go to the hospital immediately.

Other Invokana Complications

Complications from Invokana or other SGLT2 inhibitors can be serious. Most of them require hospital stays and emergency treatment. If left untreated, these complications may be life-threatening. See your doctor right away if you have symptoms of any of these conditions. You may also be entitled to financial compensation to help pay for treatment.

  • Ketoacidosis
  • Blood Infection
  • Kidney Problems
  • Blood Clots
  • Stroke

Free Invokana Case Review

    Additional Type 2 Diabetes Treatments

    People with Type 2 diabetes have numerous treatment options to discuss with their health care providers.

    The most basic recommendation is eating a healthy diet that will help patients maintain healthy weight, blood pressure, cholesterol levels and blood glucose levels. Leading a lifestyle that includes exercise or regular physical activity is also highly recommended.

    Some doctors may prescribe insulin shots, pumps or injectors. It’s important to take them as prescribed.

    All diabetes medications carry a risk of side effects, and the benefits of each medication should be greater than its risks. In addition to SGLT2 inhibitors, types of diabetes medications include:

    • Sulfonylureas
    • Biguanides
    • Meglitinides
    • Thiazolidinediones
    • DPP-4 inhibitors
    • Alpha-glucosidase inhibitors
    • Bile Acid Sequestrants

    Additional Resources for Diabetics

    It’s important for patients with Type 2 diabetes to understand their disease, because everyday activity can dramatically affect their health. Drugwatch provides resources for learning about Type 2 diabetes, including information about diabetes medications, eating a healthy diet and exercising.

    Other organizations like the American Diabetes Association, the U.S. National Library of Medicine and the National Institute of Diabetes and Digestive and Kidney Disease have a wealth of information available online.

    Patients looking for help planning healthy meals may want to consult a nutritionist or dietician. Organizations like Weight Watchers also offer weight loss and weight maintenance plans specifically designed for diabetics.

    Free Case Review

    Taking a SGLT2 Inhibitor like Invokana can lead to harmful complications including ketoacidosis. If you or your loved ones were harmed by Invokana, you may have legal options. Tell us about your experience and we will provide you with a free case review.

    Share This Page:
    Share
    View Sources
    1. Brooks, M. (2015, May 15). SGLT2 inhibitor diabetes drugs may cause ketoacidosis: FDA. Medscape. Retrieved from
    2. http://www.medscape.com/viewarticle/844754
    3. Cefalu, W.T. & Riddle, M.C. (2015). SGLT2 Inhibitors: The Latest “New Kids on the Block”! Diabetes Care. Retrieved from
    4. http://care.diabetesjournals.org/content/38/3/352.full
    5. U.S. National Library of Medicine. (2015). Label: Invokana- canagliflozin tablet, film coated. Retrieved from
    6. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3
    7. U.S. National Library of Medicine. (2015). Label: Farxiga- dapagliflozin propanediol tablet, film coated. Retrieved from
    8. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc6ae30e-868b-4ac9-b69d-900922503998#ID_dad44c90-ecc7-4931-a527-1f3a46895fda
    9. U.S. National Library of Medicine. (2015). Label: Jardiance- empagliflozin tablet, film coated. Retrieved from
    10. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565
    11. FDA. (2015, May 15). FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Retrieved from
    12. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
    13. U.S. National Library of Medicine. (2015). Diabetic ketoacidosis. Retrieved from
    14. http://www.nlm.nih.gov/medlineplus/ency/article/000320.htm
    15. Gosmanov, A. et al. (2014). Management of adult diabetic ketoacidosis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Retrieved from
    16. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085289/
    17. AstraZeneca. (2014, October 30). U.S. FDA approves once-daily Xigduo XR tablets for adults with type 2 diabetes [Press release]. Retrieved from:
    18. http://www.astrazeneca-us.com/media/press-releases/Article/20141030-us-fda-approves-oncedaily-xigduo-xr-tablets
    19. American Diabetes Association. (2015). What are my options? Retrieved from:
    20. http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/oral-medications/what-are-my-options.html
    21. National Institute of Diabetes and Digestive and Kidney Diseases. (2014). Take care of your diabetes each day. Retrieved from:
    22. http://www.niddk.nih.gov/health-information/health-topics/Diabetes/your-guide-diabetes/Pages/care.aspx
    23. FDA. (2016). Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) April - June 2016. Retrieved from http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm523358.htm
    24. Srivali, N. et al. (2015). Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus. Retrieved from http://www.jbclinpharm.org/article.asp?issn=0976-0105;year=2015;volume=6;issue=3;spage=101;epage=102;aulast=Srivali
    25. Chowdhary, M. (2015). Canagliflozin-induced pancreatitis: a rare side effect of a new drug. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489815/
    Free Invokana Case Review